| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/15/2007 | CA2617269A1 New capped pyrazinoylguanidine sodium channel blockers |
| 02/15/2007 | CA2617248A1 Methods for treating hypertension |
| 02/15/2007 | CA2617225A1 Novel heterocyclic nf-kb inhibitors |
| 02/15/2007 | CA2617161A1 Compositions and methods for treatment and prevention of hyperuricemia related health consequences |
| 02/15/2007 | CA2617101A1 Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts |
| 02/15/2007 | CA2616977A1 Oxazolidinone-quinolone hybrids as antibacterial compounds |
| 02/15/2007 | CA2616854A1 Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease |
| 02/15/2007 | CA2616721A1 Methods for treating substance-related disorders |
| 02/15/2007 | CA2616659A1 Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance |
| 02/15/2007 | CA2616451A1 Substituted benzyl derivatives as gsk-3 inhibitors |
| 02/15/2007 | CA2616428A1 Pyrazine derivatives useful as adenosine receptor antagonists |
| 02/15/2007 | CA2616424A1 New pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives |
| 02/15/2007 | CA2616249A1 A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| 02/15/2007 | CA2616214A1 Management of ophthalmologic disorders, including macular degeneration |
| 02/15/2007 | CA2616112A1 Oral suspension of prednisolone acetate |
| 02/15/2007 | CA2616075A1 Pyrazole derivatives, their manufacture and their use as pharmaceutical agents |
| 02/15/2007 | CA2616020A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| 02/15/2007 | CA2615941A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/15/2007 | CA2615760A1 Salts and polymorphs of n,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide |
| 02/15/2007 | CA2615695A1 Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents |
| 02/15/2007 | CA2615691A1 Process for the preparation of crystalline perindopril |
| 02/15/2007 | CA2615510A1 Perylenequinone derivatives and uses thereof |
| 02/15/2007 | CA2614857A1 Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| 02/15/2007 | CA2614156A1 Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
| 02/15/2007 | CA2612984A1 Antidiabetic oxazolidinediones and thiazolidinediones |
| 02/15/2007 | CA2612481A1 Stable pharmaceutical composition comprising linezolid form iv |
| 02/15/2007 | CA2612080A1 Immediate-release therapeutic systems for improved oral absorption of 7-[(e)-t-butyloxyiminomethyl] camptothecin |
| 02/15/2007 | CA2611674A1 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 02/15/2007 | CA2607226A1 Gabaergic agents to treat memory deficits |
| 02/15/2007 | CA2607219A1 Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity |
| 02/15/2007 | CA2605481A1 Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections |
| 02/14/2007 | EP1752536A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| 02/14/2007 | EP1752457A1 Fused heterocyclic compound |
| 02/14/2007 | EP1752456A1 Corneal perception recovery drug containing amide compound |
| 02/14/2007 | EP1752455A2 Chemokine receptor binding heterocyclic compounds |
| 02/14/2007 | EP1752452A1 Propane-1,3-dione derivative or its salt |
| 02/14/2007 | EP1752449A1 Pharmaceutical coposition |
| 02/14/2007 | EP1752448A2 Fluvastatin sodium crystal form lxxix, processes for preparing it, compositions containing it and methods of using it |
| 02/14/2007 | EP1752446A2 Compounds for modulating cell proliferation |
| 02/14/2007 | EP1752445A1 New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it |
| 02/14/2007 | EP1752444A1 New crystalline form IV of agometaline, the process for making it and pharmaceutical compositions containing it |
| 02/14/2007 | EP1752443A1 New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it |
| 02/14/2007 | EP1752189A2 Microprojection array having a beneficial agent containing coating |
| 02/14/2007 | EP1752164A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic |
| 02/14/2007 | EP1752162A1 Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone |
| 02/14/2007 | EP1752161A2 Pulmonary surfactans comprising a polymyxin for improving the surface properties |
| 02/14/2007 | EP1752157A1 Prevention and treatment of atherosclerosis with lithospermate B |
| 02/14/2007 | EP1752155A1 Compositions for correcting age related changes of a human endocrine system and methods for producing a pharmaceutical form bases on said compositions |
| 02/14/2007 | EP1752152A1 Agent for visualizing transparent tissue |
| 02/14/2007 | EP1752151A1 Sterol fortified beverages |
| 02/14/2007 | EP1752150A1 Irinotecan preparation |
| 02/14/2007 | EP1752149A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression |
| 02/14/2007 | EP1752148A2 Substituted phenethylsulfones for the treatment of inflammatory, infectious, immunological or malignant disease |
| 02/14/2007 | EP1752147A1 Drug for prevention or treatment of diabetes |
| 02/14/2007 | EP1752146A1 Therapeutic agent for diabetes |
| 02/14/2007 | EP1752145A1 Therapeutic agent for hyperlipemia and therapeutic agent for diabetes |
| 02/14/2007 | EP1752144A1 Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component |
| 02/14/2007 | EP1752143A1 Novel uses for drugs targeting glutamine synthetase |
| 02/14/2007 | EP1752139A1 Stable liquid formulation of paracetamol |
| 02/14/2007 | EP1752131A1 Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof |
| 02/14/2007 | EP1752129A1 Compositions and methods for treating skin conditions |
| 02/14/2007 | EP1751612A2 Methods and compositions for the treatment of uveitis |
| 02/14/2007 | EP1751553A2 Identification of anti-prion drugs by high-throughput screening based on sift |
| 02/14/2007 | EP1751312A2 Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis |
| 02/14/2007 | EP1751286A2 Biosynthetic gene cluster for the production of a complex polyketide |
| 02/14/2007 | EP1751285A2 Pharmaceutical compositions for use in the treatment of allergic diseases, pathological changes of the respiratory system and cancer via modulation of stat6 gene expression |
| 02/14/2007 | EP1751272A2 Production of tacrolimus (fk-506) using new streptomyces species |
| 02/14/2007 | EP1751172A1 Novel 3-triazolyl-galactoside inhibitors of galectins |
| 02/14/2007 | EP1751171A1 Novel galactoside inhibitors of galectins |
| 02/14/2007 | EP1751168A1 Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase |
| 02/14/2007 | EP1751167A1 Thienopyridine derivatives, production method and use thereof |
| 02/14/2007 | EP1751165A1 4-substituted 1,5-dihydro-pyrido(3,2-b)indol-2-ones |
| 02/14/2007 | EP1751164A1 3,6-diazabicyclos[3.1.1]heptane derivatives with analgesic activity |
| 02/14/2007 | EP1751163A2 Compounds having affinity for dopamine d3 receptor and uses thereof |
| 02/14/2007 | EP1751161A1 Diazaindole-dicarbonyl-piperazinyl antiviral agents |
| 02/14/2007 | EP1751159A2 Purine derivatives as a1 adenosine receptor antagonists |
| 02/14/2007 | EP1751157A1 Inhibitors of the hiv integrase enzyme |
| 02/14/2007 | EP1751156A1 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents |
| 02/14/2007 | EP1751155A1 Substituted azachinazolines having an antiviral action |
| 02/14/2007 | EP1751154A1 5-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b] indol-2-ones and analogs as anti-virals |
| 02/14/2007 | EP1751153A1 Hetaryloxy-substituted phenylamino pyrimidines as rho kinase inhibitors |
| 02/14/2007 | EP1751151A1 Pyrazolo '3,4-b! pyridine compounds, and their use as phosphodiesterase type 4 (pde4) inhibitors |
| 02/14/2007 | EP1751150A2 Novel azabicyclic aryl derivatives |
| 02/14/2007 | EP1751149A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| 02/14/2007 | EP1751148A1 Ziprasidone hydrochloride polymorph and process for its preparation |
| 02/14/2007 | EP1751147A1 New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and process to produce the same |
| 02/14/2007 | EP1751145A1 Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives |
| 02/14/2007 | EP1751144A1 Constrained himbacine analogs as thrombin receptor antagonists |
| 02/14/2007 | EP1751143A1 Pyrimidine derivatives for the treatment of abnormal cell growth |
| 02/14/2007 | EP1751142A1 Pyrimidines derivatives for the treatment of abnormal cell growth |
| 02/14/2007 | EP1751141A1 Novel pyridazinone derivatives as inhibitors of cdk2 |
| 02/14/2007 | EP1751140A1 Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
| 02/14/2007 | EP1751138A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders |
| 02/14/2007 | EP1751136A2 Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| 02/14/2007 | EP1751134A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents |
| 02/14/2007 | EP1751133A2 Compositions useful as inhibitors of rock and other protein kinases |
| 02/14/2007 | EP1751128A1 Chromene-derivatives with anti-tubulin and vascular targeting activity |
| 02/14/2007 | EP1751126A1 Alkyl carbamate-substituted butyrolactones serving as lipase inhibitors |
| 02/14/2007 | EP1751124A2 Raf modulators and methods of use |
| 02/14/2007 | EP1751121A2 Process for the preparation of anastrozole |